双氢嘧啶脱氢酶(DPD酶)是5-氟尿嘧啶(5-FU)分解代谢的最主要的限速酶,与5-FU的临床疗效密切相关.作者就DPD酶缺失、测定方法、在组织中的表达、生物调节剂以及测量其活性的单克隆抗体等作一综述.

[1] Johnson M R, WANG K, DIASIO R B. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. 2002(3)
[2] van KUILENBURG A B, MULLER E W, HAASJES J. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase(DPD) deficiency after administration of 5-fluorouracil:frequency of the common IVS14+1G&gt, A mutation causing DPD deficiency. 2001(5)
[3] van KUILENBURG A B, HAASJES J, RICHER D J. Clinical implications of dihydropyrimidine dehydrogenase(DPD)deficiency in patients with severe 5-fluorouracil-associated toxicity:identification of new mutations in the DPD gene. 2000(12)
[4] van KUILENBURG A B, DOBRITZSCH D, MEINSMA R. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. 2002
[5] van KUILENBURG A B, HAASJES J, MEINSMA R. Dihydropyrimidine dehydrogenase (DPD) deficiency:novel mutations in the DPD gene. 2000. doi:10.1007/0-306-46843-3_48
[6] van KUILENBURG A B, van LENTHE H, TROMP A. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. 2000(1)
[7] LIEM L K, CHOONG L H, WOO K T. Porous graphitic carbon shows promise for the rapid screening partial DPD deficiency in lymphocyte dihydropyrimidine dehydrogenase in Chinese,India and Malay in Singapore by using semi-automated HPLC-radioassay. 2002(3)
[8] Nozawa H, TSUKUI H, NISHIDA K. Dihydropyrimidine dehydrogenase expression in preoperative biopsy and surgically resected specimens of gastric carcinoma. 2002(4). doi:10.1007/s00280-002-0422-x
[9] HAAZ M C, FISCHEL J L, FORMENTO P. Impact of different fluorouracil biochemical modulators on cellular dihydropyrimidine dehydrogenase. 1996(1). doi:10.1007/s002800050447
[10] Beck A, ETIENNE M C, CHERADAME S. A role for dihydropyyimidine dehydrogenase and thymidylate synthase in tumor sensitivity to fluorouracil, 1994
[11] Schwartz P M, HANDSCHUMACHER R E. Selective antagonism of 5-fluorouracil cytotoxicity by 4-hydroxypyrazol pyrimidine (allopurinol) in vitro, 1979(6)
[12] BAKER S D, DIASIO R, LUCAS V S. Phase Ⅰ and pharmacologic study of oral 5-fluorouracil(5-FU) on a chronic 28-day schedule in combination with the dihydropyrimidine dehydrogenase(DPD) Inactivator 776C85, 1996(15)
[13] GREM J L, CHABNER B A, Longo D L. 5-fluoropyrimidines, 1996
[14] Levin J, HOHNEKER J. Clinical development of eniluracil/fluorouracil:an oral treatment for patients with solid tumors. 2000(4). doi:10.1023/A:1006457617467
[15] VOLK J, REINKE F, van KUILENBURG A B. Safe administration of irinotecan,oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. 2001(4). doi:10.1023/A:1011178111295
[16] Honda T, INAGAWA H, FUKUSHIMA M. Development and characterization of a monoclonal antibody with cross-reactivity towards uracil and thymine and its potential use in screening patients treated with 5-fluorouracil for possible risks. 2002(1-2). doi:10.1016/S0009-8981(2)00132-8